NEW YORK (GenomeWeb News) – Molecular data interpretation firm N-of-One today announced a deal with Fox Chase Cancer Center to provide interpretation and treatment strategy services for genome sequencing and testing.
Under the terms of the deal, N-of-One will analyze the molecular profiles and mutations identified in patients' cancers and provide treatment strategy profiles, including data on approved and investigational therapies, to Fox Chase physicians.
Based in Waltham, Mass., N-of-One interprets molecular data of patients with cancers and reports them to clinicians so that they can tailor treatments. Its lead technology is called PrecisionWorks. Because the technology can incorporate data from any sequencing platform, diagnostic, or bioinformatics system, N-of-One said, the technology can be easily integrated with Fox Chase's CancerCode-45 testing.
Fox Chase launched CancerCode-45 last month. It offers targeted sequencing using an adaptation of Life Technologies' Ion Torrent AmpliSeq Cancer Panel, as GenomeWeb Daily News' sister publication, Clinical Sequencing News, has reported.
"We believe that providing access to the latest data-driven knowledge and resources from the cancer field enables oncologists and cancer centers to be leaders in a competitive health care environment, assuring their patients that they are getting the best care possible," Jennifer Levin Carter, founder and chief medical officer of N-of-One, said in a statement.
Financial and other terms of the deal were not disclosed.
N-of-One and Foundation Medicine inked a deal last year to translate sequencing data into clinically relevant information.